Latest Headlines

Latest Headlines

MenAfriVac succeeds in sub-Saharan Africa, but the fight isn't over yet

Five years after the affordable meningitis jab, MenAfriVac, was introduced in Africa's "meningitis belt," it has nearly eliminated the disease on the continent, the World Health Organization and PATH announced on Tuesday. But scientists are warning against overconfidence, predicting that meningitis could bounce back if immunization efforts let up now.

CMC Biologics to manufacture antibodies for Malaria Vaccines Initiative

GlaxoSmithKline's malaria vaccine, Mosquirix, got an EMA green light just last month, but it doesn't mean efforts to develop additional vaccines have halted. PATH's Malaria Vaccine Initiative (MVI) is teaming up with protein manufacturer CMC Biologics to develop monoclonal antibodies that could inform future development of MVI's malaria candidates.

PATH defends itself against Indian criticisms of HPV project

Nonprofit PATH has come under attack this week after a parliamentary committee accused it of subterfuge in a human papillomavirus vaccine project that gave GlaxoSmithKline's Cervarix and Merck's Gardasil to girls in two Indian states.

PATH's Elias, Novartis' Mundel appointed to Gates Foundation positions

The Bill and Melinda Gates Foundation has been renowned for its dedication to public health and vaccine research; now it has added more talent to its roster with new heads for two of its three main

PATH calls for cheaper, more effective pneumococcal vaccines

NATIONAL HARBOR, MD-- Studies indicate that pneumococcal vaccines reduce pneumonia cases by 20 to 35 percent, according to Mark Alderson, the Director of the Pneumococcal Vaccine Project at PATH, at